Our top pick for
ObsEva SA is a biotechnology business based in the US. ObsEva shares (OBSV) are listed on the NASDAQ and all prices are listed in US Dollars. ObsEva employs 53 staff and has a trailing 12-month revenue of around USD$16,000.
|Latest market close||USD$2.01|
|52-week range||USD$1.63 - USD$6.3|
|50-day moving average||USD$2.1088|
|200-day moving average||USD$2.5901|
|Wall St. target price||USD$11.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.283|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-3.37%|
|1 month (2020-12-16)||-8.22%|
|3 months (2020-10-16)||-18.29%|
|6 months (2020-07-16)||-31.63%|
|1 year (2020-01-16)||-50.98%|
|2 years (2019-01-16)||-85.17%|
|3 years (2018-01-16)||9.7|
|5 years (2016-01-13)||N/A|
|Gross profit TTM||USD$16,000|
|Return on assets TTM||-48.56%|
|Return on equity TTM||-185.11%|
|Market capitalisation||USD$114.7 million|
TTM: trailing 12 months
There are currently 1.0 million ObsEva shares held short by investors – that's known as ObsEva's "short interest". This figure is 2.3% down from 1.1 million last month.
There are a few different ways that this level of interest in shorting ObsEva shares can be evaluated.
ObsEva's "short interest ratio" (SIR) is the quantity of ObsEva shares currently shorted divided by the average quantity of ObsEva shares traded daily (recently around 1.3 million). ObsEva's SIR currently stands at 0.79. In other words for every 100,000 ObsEva shares traded daily on the market, roughly 790 shares are currently held short.
However ObsEva's short interest can also be evaluated against the total number of ObsEva shares, or, against the total number of tradable ObsEva shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ObsEva's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 ObsEva shares in existence, roughly 20 shares are currently held short) or 0.0248% of the tradable shares (for every 100,000 tradable ObsEva shares, roughly 25 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ObsEva.
Find out more about how you can short ObsEva stock.
We're not expecting ObsEva to pay a dividend over the next 12 months.
Over the last 12 months, ObsEva's shares have ranged in value from as little as $1.63 up to $6.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ObsEva's is 0.9856. This would suggest that ObsEva's shares are less volatile than average (for this exchange).
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
Everything we know about the Bakkt Holdings IPO, plus information on how to buy in.
Everything we know about the Dream Finders Homes Inc IPO, plus information on how to buy in.
Everything we know about the Q BioMed Inc IPO, plus information on how to buy in.
Everything we know about the Faraday Future IPO, plus information on how to buy in.
Everything we know about the TELUS International Inc IPO, plus information on how to buy in.
Everything we know about the Interior Logic Group Holdings LLC IPO, plus information on how to buy in.
Everything we know about the Evaxion Biotech IPO, plus information on how to buy in.
Everything we know about the ON24 Inc IPO, plus information on how to buy in.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.